Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fletcher

Showing results (581-590 of 601) with videos related to

Pageof 61
Sort By:
Hepatology (Baltimore, Md.)|December 28, 2020
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory MediatorsOliver E Amin, Emily J Colbeck, Stephane Daffis, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2011
Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCVJ F Bergmann, J de Bruijne, D M Hotho, et al.
Antiviral Therapy|July 16, 2020
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjectsMaribel Reyes, Justin D Lutz, Audrey H Lau, et al.
Plos Pathogens|September 10, 2015
Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis BSimon P Fletcher, Daniel J Chin, Lore Gruenbaum, et al.
Gut|October 9, 2024
Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis BDavid Z Pan, Cameron M Soulette, Abhishek Aggarwal, et al.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis BRichard L Mackman, Michael Mish, Gregory Chin, et al.
JHEP Reports : Innovation in Hepatology|February 21, 2025
Hepatitis D virus infection triggers CXCL9-11 upregulation in hepatocytes and liver infiltration of CXCR3+ CD4 T cellsJan-Hendrik Bockmann, Lena Allweiss, Annika Volmari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2026
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis BEdward J Gane, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 11, 2007
Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribineAlan X Xiang, Stephen E Webber, Bradley M Kerr, et al.
Hepatology (Baltimore, Md.)|April 5, 2020
Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis BStephane Daffis, Scott Balsitis, Jason Chamberlain, et al.
Pageof 61

Showing results (581-590 of 601) with videos related to

Sort By:
Pageof 61
Hepatology (Baltimore, Md.)|December 28, 2020
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory MediatorsOliver E Amin, Emily J Colbeck, Stephane Daffis, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2011
Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCVJ F Bergmann, J de Bruijne, D M Hotho, et al.
Antiviral Therapy|July 16, 2020
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjectsMaribel Reyes, Justin D Lutz, Audrey H Lau, et al.
Plos Pathogens|September 10, 2015
Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis BSimon P Fletcher, Daniel J Chin, Lore Gruenbaum, et al.
Gut|October 9, 2024
Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis BDavid Z Pan, Cameron M Soulette, Abhishek Aggarwal, et al.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis BRichard L Mackman, Michael Mish, Gregory Chin, et al.
JHEP Reports : Innovation in Hepatology|February 21, 2025
Hepatitis D virus infection triggers CXCL9-11 upregulation in hepatocytes and liver infiltration of CXCR3+ CD4 T cellsJan-Hendrik Bockmann, Lena Allweiss, Annika Volmari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2026
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis BEdward J Gane, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 11, 2007
Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribineAlan X Xiang, Stephen E Webber, Bradley M Kerr, et al.
Hepatology (Baltimore, Md.)|April 5, 2020
Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis BStephane Daffis, Scott Balsitis, Jason Chamberlain, et al.
Pageof 61